Thermo Scientific™ Sensititre Custom Plates
Thermo Scientific™ Sensititre Custom Plates offer custom MIC frozen plates to support clinical drug trials for FDA submissions, custom plate/ancilliaries for new compound development and surveillance testing, and comparative validation studies.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Thermo Scientific™ Sensititre Custom Plates offer custom MIC frozen plates to support clinical drug trials for FDA submissions, custom plate/ancilliaries for new compound development and surveillance testing, and comparative validation studies.
Through collaboration with all major pharmaceutical companies, the Sensititre System offers an extensive range of antimicrobics available for user-defined custom plates.
- A selection from over 240 antimicrobics can be incorporated into custom formats configured to meet testing requirements
- Antimicrobic selections are provided for both full range MIC and Breakpoint testing procedures
- To meet individual laboratory test requirements, custom susceptibility plates are available in dry format and in frozen format, manufactured to meet FDA, CLSI or EUCAST guidelines
- Small minimum order quantities allow for better cost and inventory control
Thermo Fisher Scientific innovates to combat AMR with advanced antimicrobial susceptibility testing
In this video, experts from Thermo Fisher Scientific share how innovation in antimicrobial susceptibility testing (AST) is helping laboratories respond to the accelerating global challenge of antimicrobial resistance (AMR).
Speaking from a scientific and R&D perspective, Jeroen Bursens, Scientific Affairs Manager, and Jani Holopainen, Head of R&D for Microbiology, discuss how continuous panel updates, close collaboration with pharmaceutical developers, and direct engagement with customers ensure that Sensititre® broth microdilution testing remains clinically relevant in an evolving resistance landscape.
The conversation highlights emerging Gram-negative resistance mechanisms, including metallo‑β‑lactamases and carbapenem-resistant Acinetobacter baumannii, and the importance of incorporating novel antibiotics, such as aztreonam/avibactam and sulbactam/durlobactam, alongside broad, well-balanced panels to support optimal treatment decisions.
Looking ahead, the team outlines how automation, data integration, customization, and academic collaboration are shaping the future of Sensititre®, reinforcing the laboratory’s critical role in antimicrobial stewardship and the global fight against AMR.
Interview recorded at ESCMID Global 2026.
